These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Epstein-barr virus-associated smooth muscle tumors after bone marrow transplantation. Hayase E; Fujimoto K; Mitsuhashi T; Hatanaka Y; Yoshida M; Takemura R; Iwasaki J; Shiratori S; Sugita J; Kondo T; Tanaka J; Imamura M; Matsuno Y; Teshima T Transplantation; 2014 Jan; 97(1):e1-3. PubMed ID: 24374766 [No Abstract] [Full Text] [Related]
9. Prodrome of disseminated varicella zoster in an immunocompromised adult. Beaty O; Engel J; Jones B; Raab M N C Med J; 1992 Feb; 53(2):71-3. PubMed ID: 1557136 [No Abstract] [Full Text] [Related]
10. Varicella-zoster virus infections in the immunocompromised host. Natural history and treatment. Balfour HH Scand J Infect Dis Suppl; 1991; 80():69-74. PubMed ID: 1666447 [TBL] [Abstract][Full Text] [Related]
11. Postexposure prophylaxis against varicella-zoster virus infection among recipients of hematopoietic stem cell transplant: unresolved issues. Weinstock DM; Boeckh M; Boulad F; Eagan JA; Fraser VJ; Henderson DK; Perl TM; Yokoe D; Sepkowitz KA Infect Control Hosp Epidemiol; 2004 Jul; 25(7):603-8. PubMed ID: 15301035 [TBL] [Abstract][Full Text] [Related]
12. [Reactivation of herpes zoster infection by varicella-zoster virus]. Cvjetković D; Jovanović J; Hrnjaković-Cvjetković I; Brkić S; Bogdanović M Med Pregl; 1999; 52(3-5):125-8. PubMed ID: 10518396 [TBL] [Abstract][Full Text] [Related]
13. Recovery of varicella-zoster virus-specific T cell immunity after T cell-depleted allogeneic transplantation requires symptomatic virus reactivation. Distler E; Schnürer E; Wagner E; von Auer C; Plachter B; Wehler D; Huber C; Kolbe K; Meyer RG; Herr W Biol Blood Marrow Transplant; 2008 Dec; 14(12):1417-24. PubMed ID: 19041065 [TBL] [Abstract][Full Text] [Related]
14. Ready-to-use T cells for infection after stem-cell transplant. Gilbert JA Lancet Oncol; 2017 Sep; 18(9):e519. PubMed ID: 28826590 [No Abstract] [Full Text] [Related]
15. A new step toward individualized antifungal prevention in hematopoietic stem cell transplantation. Bochud PY; Calandra T Clin Infect Dis; 2009 Sep; 49(5):733-5. PubMed ID: 19614558 [No Abstract] [Full Text] [Related]
16. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. Hata A; Asanuma H; Rinki M; Sharp M; Wong RM; Blume K; Arvin AM N Engl J Med; 2002 Jul; 347(1):26-34. PubMed ID: 12097537 [TBL] [Abstract][Full Text] [Related]
17. Humoral and cellular immunity to varicella-zoster virus: an overview. Arvin AM J Infect Dis; 2008 Mar; 197 Suppl 2():S58-60. PubMed ID: 18419410 [No Abstract] [Full Text] [Related]
19. Inappropriate antidiuretic hormone secretion, abdominal pain and disseminated varicella-zoster virus infection: an unusual triad in a patient 6 months post mini-allogeneic peripheral stem cell transplant for chronic myeloid leukemia. Szabó F; Horvath N; Seimon S; Hughes T Bone Marrow Transplant; 2000 Jul; 26(2):231-3. PubMed ID: 10918438 [TBL] [Abstract][Full Text] [Related]
20. Experience with use of Zostavax(®) in patients with hematologic malignancy and hematopoietic cell transplant recipients. Naidus E; Damon L; Schwartz BS; Breed C; Liu C Am J Hematol; 2012 Jan; 87(1):123-5. PubMed ID: 22052650 [No Abstract] [Full Text] [Related] [Next] [New Search]